AEON Biopharma, Inc. (AEON)
(Delayed Data from AMEX)
$2.25 USD
-0.31 (-12.11%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $2.28 +0.03 (1.33%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Price, Consensus and EPS Surprise
AEON 2.25 -0.31(-12.11%)
Will AEON be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AEON based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AEON
Down -64.16% in 4 Weeks, Here's Why AEON Biopharma, Inc. (AEON) Looks Ripe for a Turnaround
AEON Biopharma, Inc. (AEON) Loses -79.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
AEON: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why AEON Biopharma, Inc. (AEON) Is a Great 'Buy the Bottom' Stock Now
Other News for AEON
3 Penny Stocks to Watch Now, 7/18/24
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
AEON Biopharma Announces Strategic Reprioritization to Pursue a Biosimilar Pathway for ABP-450
Buy Rating Affirmed for AEON Biopharma: Strategic Cost-Cutting and ABP-450’s Broad Market Potential
AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan